A bill that would give FDA a $341 million hike in discretionary funding in fiscal 2023 passed out of the House Appropriations Committee Thursday (June 23) with new measures that prohibit FDA from using funding to review and approve drugs made by Russian companies, direct FDA to coordinate with U.S. Customs and Border Protection to curb the importation of illicit fentanyl into the United States, and ask the agency to collaborate with the U.S. Department of Agriculture to oversee genetically...